News
By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback